Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 8/20 | 0.75 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29423333 | 0.86 | TAAR1 (1.00) | TAAR1IDO1GPR52HTR2A | |
| SCHEMBL265615 | 0.86 | TAAR1 (1.00) | TAAR1IDO1GPR52HTR2A | |
| Iodide SCHEMBL28685278 | 0.84 | TAAR1 (0.95) | TAAR1IDO1GPR52HTR2A | |
| Bromide SCHEMBL31622102 | 0.84 | TAAR1 (0.95) | TAAR1IDO1GPR52HTR2A | |
| Hydrochloric Acid SCHEMBL533785 | 0.84 | TAAR1 (0.95) | TAAR1IDO1GPR52HTR2A | |
| SCHEMBL29943451 | 0.83 | TAAR1 (0.50) | TAAR1MAOAHTR2A | |
| SCHEMBL3678681 | 0.83 | TAAR1 (0.50) | TAAR1MAOAHTR2A | |
| SCHEMBL4011586 | 0.82 | TAAR1 (0.61) | TAAR1IDO1GPR52TSHR | |
| SCHEMBL31627173 | 0.81 | TAAR1 (0.60) | TAAR1IDO1MAOA | |
| SCHEMBL9175222 | 0.80 | TAAR1 (0.59) | TAAR1IDO1GPR52TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144795-A1 | SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS | H. LUNDBECK A/S (DK) | 2026-05-28 | — | — | US | disclosed |
| US-11459307-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX LLC (US) | 2022-10-04 | — | — | US | disclosed |
| CN-112724084-B | Preparation method of (S) -5-bromo-1, 2,3, 4-tetrahydro-N-Boc-isoquinoline-1-carboxylic acid | 上海彩迩文生化科技有限公司 | 2022-04-22 | — | — | CN | disclosed |
| US-20210198216-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX LLC (US) | 2021-07-01 | — | — | US | disclosed |
| US-20210198216-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX LLC (US) | 2021-07-01 | — | — | US | disclosed |
| CN-112724084-A | Preparation method of (S) -5-bromo-1, 2,3, 4-tetrahydro-N-Boc-isoquinoline-1-carboxylic acid | 南京艾普特生物医药有限公司 | 2021-04-30 | — | — | CN | disclosed |
| CN-109111383-B | 2-substituted diphenyl sulfide derivative and use thereof | 广东东阳光药业有限公司 | 2020-11-24 | — | — | CN | disclosed |
| US-10781185-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX LLC (US) | 2020-09-22 | — | — | US | disclosed |
| US-10781185-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX LLC (US) | 2020-09-22 | — | — | US | disclosed |
| CN-109111383-A | The diphenyl sulfide derivative and application thereof that 2- replaces | 广东东阳光药业有限公司 | 2019-01-01 | — | — | CN | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| WO-2009023964-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2009-02-26 | — | — | WO | disclosed |
| US-20070249682-A1 | Novel CD40:CD154 binding interruptor compounds and use thereof to treat immunological complications | ZHENG ZHONGLI | 2007-10-25 | — | — | US | disclosed |
| US-20070249682-A1 | Novel CD40:CD154 binding interruptor compounds and use thereof to treat immunological complications | ZHENG ZHONGLI | 2007-10-25 | — | — | US | disclosed |
| CN-101039907-A | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2007-09-19 | — | — | CN | disclosed |
| EP-1778634-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | AstraZeneca AB (SE) | 2007-05-02 | — | — | EP | disclosed |
| US-7173046-B2 | CD40:CD154 binding interrupter compounds and use thereof to treat immunological complications | BIOGEN, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173046-B2 | CD40:CD154 binding interrupter compounds and use thereof to treat immunological complications | BIOGEN, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| WO-2006020879-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006020879-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144795-A1 | SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS | HCRTR2, HCRTR1, CRHR1 | TAAR1 61/4885IDO1 1291/4885MAOA 452/4885 |
| US-20070249682-A1 | Novel CD40:CD154 binding interruptor compounds and use thereof to treat immunological complications | CD40, CD40LG, TNFSF11 | TAAR1 4186/4885IDO1 659/4885MAOA 4428/4885 |
| US-11459307-B2 | Heterocyclic compounds for the inhibition of PASK | PASK, PDXK, PANK2 | TAAR1 4451/4885IDO1 4379/4885MAOA 1508/4885 |
| US-20210198216-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | TAAR1 4451/4885IDO1 4379/4885MAOA 1508/4885 |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM3 | TAAR1 286/4885IDO1 1586/4885MAOA 4014/4885 |
| US-10781185-B2 | Heterocyclic compounds for the inhibition of PASK | PASK, PDXK, PANK2 | TAAR1 4451/4885IDO1 4379/4885MAOA 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.